[go: up one dir, main page]

WO2000049990A3 - The process for manufacturing topical ophthalmic preparations without systemic effects - Google Patents

The process for manufacturing topical ophthalmic preparations without systemic effects Download PDF

Info

Publication number
WO2000049990A3
WO2000049990A3 PCT/IN2000/000008 IN0000008W WO0049990A3 WO 2000049990 A3 WO2000049990 A3 WO 2000049990A3 IN 0000008 W IN0000008 W IN 0000008W WO 0049990 A3 WO0049990 A3 WO 0049990A3
Authority
WO
WIPO (PCT)
Prior art keywords
systemic effects
topical ophthalmic
ophthalmic preparations
manufacturing
manufacturing topical
Prior art date
Application number
PCT/IN2000/000008
Other languages
French (fr)
Other versions
WO2000049990A2 (en
Inventor
Bakulesh Mafatlal Khamar
Original Assignee
Bakulesh Mafatlal Khamar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bakulesh Mafatlal Khamar filed Critical Bakulesh Mafatlal Khamar
Priority to BR0004530-6A priority Critical patent/BR0004530A/en
Priority to EP00925571A priority patent/EP1139970A2/en
Priority to CA002326690A priority patent/CA2326690A1/en
Priority to AU44291/00A priority patent/AU4429100A/en
Priority to EA200000918A priority patent/EA200000918A1/en
Priority to IL13882400A priority patent/IL138824A0/en
Priority to APAP/P/2000/001977A priority patent/AP2000001977A0/en
Publication of WO2000049990A2 publication Critical patent/WO2000049990A2/en
Publication of WO2000049990A3 publication Critical patent/WO2000049990A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to topical ophthalmic preperations resp. a process for manufacturing the same using polymers in such a way that they have desired topical effects but no systemic effects. The polymers (e.g. polyacrylic acids, hydroxyethyl cellulose, etc.) used for this purpose have pseudo-plastic, mucoadhesive and viscosity enhancing properties.
PCT/IN2000/000008 1999-02-03 2000-02-02 The process for manufacturing topical ophthalmic preparations without systemic effects WO2000049990A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
BR0004530-6A BR0004530A (en) 1999-02-03 2000-02-02 Process for manufacturing topical ophthalmic preparations without systemic effects
EP00925571A EP1139970A2 (en) 1999-02-03 2000-02-02 The process for manufacturing topical ophthalmic preparations without systemic effects
CA002326690A CA2326690A1 (en) 1999-02-03 2000-02-02 The process for manufacturing topical ophthalmic preparations without systemic effects
AU44291/00A AU4429100A (en) 1999-02-03 2000-02-02 The process for manufacturing topical ophthalmic preparations without systemic effects
EA200000918A EA200000918A1 (en) 1999-02-03 2000-02-02 METHOD OF MANUFACTURING THE EYE DRUGS OF LOCAL APPLICATION WITHOUT GENERAL ACTIONS
IL13882400A IL138824A0 (en) 1999-02-03 2000-02-02 Process for manufacturing topical ophthalmic preparations without systemic effects
APAP/P/2000/001977A AP2000001977A0 (en) 1999-02-03 2000-02-02 The process for manufacturing topical opthalmic preparations without systemic effects.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN90/BOM/99 1999-02-03
IN90BO1999 IN185228B (en) 1999-02-03 1999-02-03

Publications (2)

Publication Number Publication Date
WO2000049990A2 WO2000049990A2 (en) 2000-08-31
WO2000049990A3 true WO2000049990A3 (en) 2001-07-26

Family

ID=11077485

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2000/000008 WO2000049990A2 (en) 1999-02-03 2000-02-02 The process for manufacturing topical ophthalmic preparations without systemic effects

Country Status (11)

Country Link
EP (1) EP1139970A2 (en)
AP (1) AP2000001977A0 (en)
AU (1) AU4429100A (en)
BR (1) BR0004530A (en)
CA (1) CA2326690A1 (en)
EA (1) EA200000918A1 (en)
ID (1) ID28121A (en)
IL (1) IL138824A0 (en)
IN (1) IN185228B (en)
WO (1) WO2000049990A2 (en)
ZA (1) ZA200006252B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005220199B2 (en) * 2000-07-14 2007-03-08 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
AU7326901A (en) * 2000-07-14 2002-01-30 Allergan Sales Inc Compositions containing alpha-2-adrenergic agonist components
US8858961B2 (en) 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
DE10132876A1 (en) * 2001-07-06 2003-01-30 Medproject Pharma Entwicklungs Two-phase, drop-onable hydrogels for use on the eye
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
SI1761266T1 (en) 2004-05-25 2013-08-30 Galderma Pharma S.A. Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
EP2329849B1 (en) 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
FR2977493B1 (en) 2011-07-05 2014-02-14 Galderma Res & Dev NOVEL STABLE ANESTHETIC COMPOSITION FOR REDUCING SKIN REACTIONS
HK1218850A1 (en) 2013-02-15 2017-03-17 Allergan, Inc. Sustained drug delivery implant
WO2014150899A1 (en) * 2013-03-15 2014-09-25 Chapin Matthew J Topical ophthalmic formulations for treating migraine
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition
EP3302426A4 (en) 2015-05-29 2018-12-05 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
GB202110420D0 (en) * 2021-07-20 2021-09-01 Rosemont Pharmaceuticals Ltd Liquid pharmaceutical composition of clonidine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD294174A5 (en) * 1990-05-04 1991-09-26 Sigrid Keipert OPHTHALMIKA WITH RESET EFFECT AND A NEW PROCESS FOR THEIR MANUFACTURE
WO1993000887A1 (en) * 1991-07-10 1993-01-21 Laboratoire Europhta S.A. Polyacrylic acid based ophthalmic compositions
WO1993002663A1 (en) * 1991-07-30 1993-02-18 Laboratoires Merck Sharp & Dohme-Chibret Ophthalmic compositions based on polyhydric alcohols
EP0801948A1 (en) * 1996-04-15 1997-10-22 Dr. GERHARD MANN chem.-pharm. Fabrik GmbH Ophthalmic composition having prolonged residence time in the eye

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6056684B2 (en) * 1977-11-07 1985-12-11 東興薬品工業株式会社 eye drops

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD294174A5 (en) * 1990-05-04 1991-09-26 Sigrid Keipert OPHTHALMIKA WITH RESET EFFECT AND A NEW PROCESS FOR THEIR MANUFACTURE
WO1993000887A1 (en) * 1991-07-10 1993-01-21 Laboratoire Europhta S.A. Polyacrylic acid based ophthalmic compositions
WO1993002663A1 (en) * 1991-07-30 1993-02-18 Laboratoires Merck Sharp & Dohme-Chibret Ophthalmic compositions based on polyhydric alcohols
EP0801948A1 (en) * 1996-04-15 1997-10-22 Dr. GERHARD MANN chem.-pharm. Fabrik GmbH Ophthalmic composition having prolonged residence time in the eye

Also Published As

Publication number Publication date
CA2326690A1 (en) 2000-08-31
AU4429100A (en) 2000-09-14
EA200000918A1 (en) 2001-10-22
AP2000001977A0 (en) 2000-12-31
IL138824A0 (en) 2001-10-31
WO2000049990A2 (en) 2000-08-31
BR0004530A (en) 2001-04-03
EP1139970A2 (en) 2001-10-10
ID28121A (en) 2001-05-03
ZA200006252B (en) 2001-11-29
IN185228B (en) 2000-12-09

Similar Documents

Publication Publication Date Title
WO2000049990A3 (en) The process for manufacturing topical ophthalmic preparations without systemic effects
WO2003011226A3 (en) Products and drug delivery vehicles
DE60135872D1 (en) ABSACK PREVENTION OF ISOROUTS USED IN THE MANUFACTURE OF FLAT GLASS AFTER THE MELTING PROCESS
WO1998016507A3 (en) New heterocyclylmethyl-substituted pyrazol derivates and their use for treating cardiovascular diseases
AU2002256420A1 (en) System and process for providing institutional directed sponsored trading
AU2002328294A1 (en) Water-soluble antibiotic comprising an amino sugar, in the form of a polysaccharide conjugate
EE03923B1 (en) S-omeprazole in neutral form, process for its preparation and pharmaceutical compositions containing it
MXPA03007591A (en) Compositions and methods for enhancing drug delivery across and into epithelial tissues.
AU2001234466A1 (en) Tunable indocyanine dyes for biomedical applications
HUP0303735A3 (en) Pyrazole derivatives for treating hiv, pharmaceutical compositions containing them and process for their preparation
ZA200109859B (en) 6-Alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations.
EE03338B1 (en) Anti-thrombotic drug, process for its preparation and use
WO2002100437A3 (en) Ophthalmic compositions comprising hyaluronic acid
WO2004087043A3 (en) Stable ophthalmic formulation containing an antibiotic and a corticosteroid
WO2002043706A3 (en) Prolamin-based sustained-release compositions and delayed-onset compositions
IT1305313B1 (en) 3,4 - DIHYDRO- 6- BENZYL-4-OXOPYRIMIDINE REPLACED AND RELATED PROCESS OF PRODUCTION AND USE IN THE THERAPY OF HIV-1 INFECTIONS.
WO2002074036A3 (en) Substituted benzopyranones as telomerase inhibitors
AU3501800A (en) Aqueous dispersion composition and manufacturing method for the composition
NO20033318L (en) 2H-1-benzopyran derivatives, process of manufacture, and pharmaceutical compositions thereof
WO2001005414A8 (en) Algae protein polysaccharide extraction and use thereof
AU3825700A (en) Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines
FI20002102A0 (en) The method of redemption / delivery of a product, service, payment and / or similar
CA2370125A1 (en) Decorative cosmetic preparations
AU2001254812A1 (en) 9-oxa-epothilon derivatives, method for the production and use thereof in pharmaceutical preparations
AU2002245979A1 (en) Process for making protein delivery matrix and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AU BA BB BG BR CA CN CR CU CZ EE GE HU ID IL IS KP KR LC LK LR LS LT LV MG MK MN MX NO PL RO SG SI SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 09719704

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2326690

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000925571

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/009715

Country of ref document: MX

Ref document number: 138824

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 200000918

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: PV2000-3761

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1200000931

Country of ref document: VN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2000/06252

Country of ref document: ZA

Ref document number: 200006252

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 508027

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: P20000818-A

Country of ref document: HR

WWR Wipo information: refused in national office

Ref document number: PV2000-3761

Country of ref document: CZ

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AU BA BB BG BR CA CN CR CU CZ EE GE HU ID IL IS KP KR LC LK LR LS LT LV MG MK MN MX NO PL RO SG SI SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000925571

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000925571

Country of ref document: EP